We Fuel a Network of Leaders that Drive Virginia Bioscience

We are made up of the people who do the research, development and commercialization of biosciences in Virginia, and the suppliers, consultants, attorneys, accountants and others who work to support the industry.

Summer 2022 Internship

Our Sponsors

Driven by Innovation & Growth

Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.

About Us

Virginia's Life Science Community By the Numbers

  • 1,451 Companies

    Life science companies in Virginia.

  • $8B Industry

    Life Science contributes $8B to Virginia's economy.

  • 26,545 People

    Employed by Life Science companies in Virginia.

  • $77,848 Average Wage

    Average earnings of life science workers in Virginia.

  • 1,197 Clinical trials

    Biopharmaceutical industry-sponsored trials in Virginia per year.

Upcoming Events

Solving the Unsolvable: Could Quantum and other Non-traditional Computing hold the key to accelerating drug development?

12/07/2021

11:00 am  – 12:30 pm  EST

December 2021 Commercialization Luncheon

12/09/2021  – 12/09/2021

12:00 pm  – 1:00 pm  EST

Bench to Community: Building Your Start-up Team

12/16/2021  – 12/16/2021

4:00 pm  – 5:30 pm  EST

Virginia Reception at J.P. Morgan Healthcare Week

01/09/2022  – 01/09/2022

6:00 pm  – 8:00 pm  EST

News

11/30/2021

Landos Biopharma Announces Leadership Transition

Landos Biopharma Inc. ,a clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and Chief Executive Officer, effective immediately. Tim M. Mayleben, a member of the Landos Board, has been

11/30/2021

Richmond pharma company Kaléo Acquired

New York-based Marathon Asset Management LP announced it has entered into a definitive agreement to acquire Richmond-based privately held pharmaceutical company Kaléo Inc., which is known for treating allergic anaphylaxis and opioids overdoses. The total base purchase price is approximately $310 million in cash, less certain adjustments and includes potential net revenue-based milestone payments of

11/19/2021

Study aiming to define acute traumatic encephalopathy (ATE) published by leading neurology journal

BrainBox HeadSmart II Study Investigators Aim to Provide Clinicians with First-Ever Biomarkers and other Functional measurements for Acute Traumatic Encephalopathy (ATE.) A clinical trial of multi-modal diagnostic/prognostic test, already underway, is published in Frontiers in Neurology/NeuroTrauma. Investigators in a major clinical trial of patients with mild traumatic brain injury (mTBI or concussion) describe for the